Should treatment of Parkinson's disease be started with a dopamine agonist?

Neurology

Volumn 51, Issue 2 SUPPL., 1998, Pages

  Poewe, Werner ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DYSKINESIA; FUNCTIONAL ASSESSMENT; HUMAN; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031684367     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.2_suppl_2.s21     Document Type: Conference Paper

References (33)

1. Lindvall O, Sawle G, Widner H, et al. Evidence for long term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35:172-180.
2. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
3. Wenning GK, Odin P, Morrish PK, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997;42:95-107.
4. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
5. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777.
6. Koller WC. Selegiline monotherapy in the treatment of Parkinson's disease. Neurology 1996;47:196-199.
7. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418.
8. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344-rats. Neurobiol Aging 1992;13:339-351.
9. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 1994;657:207-213.
10. Winkler C, Sauer H, Lee CS, Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopamine neurons in a rat model of Parkinson's disease. J Neurosci 1996;16:7206-7215.
11. Poewe W, Granata R. Pharmacological treatment of Parkinson's disease. In: RL Watts, WC Koller, eds. New York: McGraw Hill, Movement disorders, neurologic principles and practice. 1997:201-219.
12. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307: 469-472.
13. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-685.
14. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year L-dopa-controlled study. Mov Disord 1998;13:39-45.
15. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
16. Olsson JE, Rascol A, Korten JJ, Dupont E, Gauthier G. Early treatment with a combination of bromocriptine and levodopa compared with levodopa monotherapy in the treatment of Parkinson's disease. Curr Ther Res 1989;46:1002-1014.
17. UK Bromocriptine Research Group. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry 1989;52:77-82.
18. Przuntek H, Welzel D, Blümner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992;43:357-363.
19. Montrastuc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a 5-year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
20. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435.
21. Mena MA, Casarejos MJ, Carazo A, Paino CL, De Yebenes JG. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity. Neuroreport 1996;7:441-445.
22. Basma AN, Morris EJ, Nicklas WJ, Geller HM. L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 1995;64:825-832.
23. Offen D, Ziv I, Gorodin S, Panet H, Melamed E. Dopamine-melanin induces apoptosis PC12 and neuronal cells: possible implications for therapeutic approaches in Parkinson's disease [Abstract]. Mov Disord 1996;11:45.
24. Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E. Dopamine-induced, genotoxic activation of programmed cell death: a role in nigrostriatal neuronal degeneration in Parkinson's disease? Adv Neurol 1996;69:229-233.
25. Pardo B, Mena MA, Casarejos MJ, Paino CL, De Yebenes JG. Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants. Brain Res 1995;682:133-143.
26. Steece-Collier K, Yurek DM, Collier TJ, Junn FS, Sladek JR. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing. Brain Res 1995;676: 404-408.
27. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
28. Przedborski S, Jackson-Lewis V, Fahn S. Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov Disord 1995;10:312-317.
29. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-256.
30. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a 4-year period. Mov Disord 1986;1:65-68.
31. Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to non-degenerating substantia nigra cells? Clinical evidence [Abstract]. Neurology 1996;46:A371.
32. Reches A, Fahn S. Chronic dopa feeding of mice. Neurology 1982;32:684-685.
33. Dziewczapolski G, Murer G, Agid Y, Gershanik OS, Raisman-Vozari R. Absence of neurotoxicity of chronic L-dopa in 6-hydroxydopamine-lesioned rats. Neuroreport 1997;8:975-979.